SCHEMBL3870804

SCHEMBL3870804

O=C(O)c1cc2c(NC(=O)c3ccccc3NC(=O)c3ccccc3F)n[nH]c2s1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
L3MBTL1 Q9Y468 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
KMT2A Q03164 2/20 0.41
BCL3 P20749 1/20 0.41
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
RXFP1 Q9HBX9 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 1/20 0.40
KCNMA1 Q12791 1/20 0.40
GPR35 Q9HC97 1/20 0.39
TP53 P04637 1/20 0.39
PKM P14618 1/20 0.39
ALOX15 P16050 1/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4631861 0.96 RAB9A (0.48) NPC1RAB9AL3MBTL1TDP1KMT2A
SCHEMBL3866786 0.89 KDM4E (0.48) NPC1RAB9ATDP1KMT2ARXFP1
SCHEMBL3872962 0.89 CYP1A2 (0.48) NPC1RAB9AKMT2AALDH1A1MEN1
SCHEMBL3872653 0.87 ALDH1A1 (0.43) RAB9AL3MBTL1KMT2AGAARXFP1
SCHEMBL3866586 0.87 POLB (0.42) NPC1RAB9AL3MBTL1TDP1KMT2A
SCHEMBL2416300 0.87 POLB (0.46) NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1
SCHEMBL2420086 0.86 NPC1 (0.50) NPC1RAB9ATDP1KMT2ASMN1; SMN2
SCHEMBL1778129 0.86 AURKA (0.43) NPC1RAB9AL3MBTL1TDP1SMN1; SMN2
SCHEMBL3875203 0.85 TSHR (0.51) NPC1RAB9AL3MBTL1KMT2ASMN1; SMN2
SCHEMBL3872706 0.85 KCNMA1 (0.38) NPC1RAB9AL3MBTL1TDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 NPC1 2677/4885RAB9A 2971/4885L3MBTL1 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.